That estimated enrollment number of 15 is very interesting.
Reads to me like they anticipate a 30% progression rate from the CVac arm.
That it much less than the 90% we would expect from the non-CVac arm.
Hard to say for sure though. There may be other reasons for limiting it to 15.
Perhaps add that to the list of shareholder questions...
2b trial variation-safety profile assessment, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.8¢ | 33.5¢ | $932.8K | 2.725M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29411 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 938315 | 11 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |